Login to Your Account



Merck keeps rolling along with plans to sharpen focus

By Peter Winter
BioWorld Insight Editor

Tuesday, January 14, 2014
Back in October 2013, Merck & Co. Inc. chairman and CEO Kenneth C. Frazier announced a major strategic restructuring to create “greater efficiencies” for the company. The goal: to put its R&D operations in order and pare its annual operating expenses by approximately $2.5 billion by the end of 2015.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription